1. Home
  2. TNXP vs FINW Comparison

TNXP vs FINW Comparison

Compare TNXP & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$12.79

Market Cap

192.9M

Sector

Health Care

ML Signal

HOLD

Logo FinWise Bancorp

FINW

FinWise Bancorp

HOLD

Current Price

$14.90

Market Cap

194.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
FINW
Founded
2007
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
192.9M
194.4M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
TNXP
FINW
Price
$12.79
$14.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
525.4K
14.0K
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
21.51
EPS
N/A
0.20
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
$160.48
Revenue Next Year
$38.29
$35.27
P/E Ratio
N/A
$72.75
Revenue Growth
29.85
N/A
52 Week Low
$10.03
$12.82
52 Week High
$69.65
$22.49

Technical Indicators

Market Signals
Indicator
TNXP
FINW
Relative Strength Index (RSI) 57.23 59.52
Support Level $12.43 $13.51
Resistance Level $15.19 $17.39
Average True Range (ATR) 1.01 0.40
MACD 0.20 0.07
Stochastic Oscillator 87.20 97.11

Price Performance

Historical Comparison
TNXP
FINW

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

Share on Social Networks: